fbpx

Gut microbiota and heart disease: Understanding the links

Gut microbiota and heart disease: Understanding the links

The gut microbiota is a massive community of microorganisms that live in our gastrointestinal tract, where they help our body fight off infections, produce chemicals that feed our cells and influence our physiology and metabolism1-2.

In recent years, multiple studies have reported on the link between gut microbiota and heart disease, a link that involves a wide range of factors. For example, intestinal-derived chemicals such as lipopolysaccharides3, indoxyl sulfate4, and para-cresyl sulfate5have shown to have important metabolic roles in conditions like atherosclerosis and cardio-renal dysfunction.

 

Gut Microbiota and health

 

The human gut is home for more than 100 trillion bacteria from hundreds of different species, as well as for other microorganisms like viruses and fungi6. In recent decades, research has identified multiple important roles for the human gut microbiota, such as:

      • Improving host nutrition and energy productivity7
      • Maintenance of epithelial homeostasis8
      • Interaction with drug metabolism and toxicity9
      • Influencing immune function10
      • Protecting our body from invading pathogens11

 

The gut microbiota are also important producers of chemicals like uremic toxins, bile acids, trimethylamine-N-oxide (TMAO), short-chain fatty acids (SCFA), lipopolysaccharides (LPS), nitric oxide, vitamin K, vitamin B complex, gut hormones, and neurotransmitters12-20. These chemicals have different and important roles in our body metabolism and influence multiple functions in our body during health and disease.

Studies have identified associations between gut dysbiosis and metabolic disorders (like obesity or diabetes) and cardiovascular disease, including condition like atherosclerosis, dyslipidemia, hypertension, and heart failure21-25. Gut microbiota influences this condition through direct and indirect pathways. Direct pathways involve the chemicals produced by these microbes, called metabolites, whereas indirect pathways involve the influence gut microbes have on the immune system21,10.

 

Focus on: Gut Microbiota and Heart Disease

 

Heart disease, also known as Cardiovascular Disease (CVD) is the number 1 cause of death worldwide, killing nearly 18 million people each year, according to the World Health Organization. In Australia, more than 41,000 people die each year from heart-related conditions.

Heart disease includes a large number of conditions, such as coronary heart disease, cerebrovascular disease, rheumatic heart disease, angina, heart arrhythmias, heart attack, heart failure, and many others. For a complete let, head to this governmental site. Among these conditions heart attacks and strokes are the most common, representing 4 our 5 deaths due to CVD.

Studies have found links with the composition of the gut microbiota and many of these conditions, including:

 

      • Atherosclerosis

        This condition occurs when blood vessels become narrow, due to the accumulation of plaque, a substance mostly made up of fat and cholesterol. When too much of this plaque accumulated in the veins and arteries, blood cannot flow freely, affecting the delivery of oxygen to vital organs. When this happens in the arteries leading to the heart, conditions like heart attacks or heart failure can occur.

 

Multiple risk factors are associated with atherosclerosis, including unhealthy diets rich in fats and sugar, smoking, lack of physical activity and certain conditions, like diabetes, high blood pressure, and obesity/overweight, among others.

In recent years, studies have recognised a role for the composition of the gut microbiota in the development of atherosclerosis. One study, for example, found that people with asymptomatic atherosclerotic plaques have an increased abundance of gut bacteria of the Porphyromonadaceae, Bacteroidaceae, Micrococcacaea, and Streptococcacaea families26. Asymptomatic atherosclerotic plaques are a mild form of atherosclerosis that does not have noticeable symptoms, as blood flow is not significantly affected. In contrast, people with symptomatic atherosclerotic plaques contained an increased abundance of pathogenic gut bacteria, including members of the Helicobacteracaea, Neisseriaceae, and Thiotrichacaea families.

Gut dysbiosis, where there is an alteration of the normal composition of a person’s gut microbiota has also been associated with the development of atherosclerosis27. Here, gut microbiota has been shown to activate inflammatory pathways that alter the way our body process fats in adipocytes (fat cells), macrophages (immune cells) and vascular cells27.

 

      • Hypertension

        This is the most common risk factor associated with cardiovascular disease and the main cause of disability and death in developed countries. Hypertension occurs when a person has a blood pressure reading of more than 140/90 mmHg. Worldwide, it is estimated to affect as many as 13 billion people28. In Australia, 1 in 3 adults over the age of 18 has hypertension. Multiple factors are associated with high blood pressure, including lack of exercise, smoking, being overweight, following a diet high in salt, your genetic background, high alcohol consumption and conditions like diabetes.

 

Recently, the composition of the gut microbiota has also been linked to the development of hypertension. One study, for example, found that people who suffer from hypertension have a lower diversity of their gut microbiota, and different composition, with an overrepresentation of bacteria from the genus Prevotella, compared to people with no hypertension29-30. Short-chain fatty acids (SCFAs), which are chemicals produced by some gut bacteria, have also been associated with hypertension. Some of these chemicals, for example, have been shown to interact with specific proteins in our body that can lead to hypertension31-32.

 

      • Heart Failure

        This condition occurs when the heart is not able to pump blood normally, due to damage to structure and function of the heart. Some common symptoms of heart failure include shortness of breath, loss of appetite, tiredness, weight gain, swollen legs, ankles, belly or feet, dizziness and coughing. In many forms of heart disease, like coronary heart disease, heart attack, or high blood pressure, heart failure represents the final stage of the disease, leading to a heart attack and death. Current studies have found significant evidence for the role of gut microbiota in the development and progression of heart failure. For example, one study found that patients suffering from heart failure have been found to host higher levels of pathogenic bacteria, such as Campylobacter, Shigella, Salmonella and Yersinia enterocolitica, compared to healthy people. Also, bacterial species from the Candida, Campylobacter and Shigella genera were positively correlated with the severity of heart failure33-34. Heart failure has also been associated with increased levels of Escherichia coli, Klebsiella penumoniae, and Streptococcus viridans, according to another study35.

 

Another study found a link between gut bacteria and the effectiveness of drugs used to treat heart failure. For example, the drug digoxin could be inactivated by the but bacteria Eggerthella lenta36. Likewise, the composition of a person’s gut microbiota can lead to specific metabolic profiles that can affect how heart failure drugs function37. Hence, it important to understand the gut bacterial composition of each patient to identify potential interactions between drugs and bacteria.

 

Beyond atherosclerosis, hypertension and heart failure, studies have also identified links between the gut microbiota and conditions like stroke, transient ischemic attack, and variations the levels of fats in the blood38-39.

 

The Modern Functional Medicine approach

 

At the Australian Centre for Functional Medicine, we have an in-depth understanding of the different factors that affect heart disease. We take a comprehensive approach to the diagnosis and treatment of patients at high risk of developing heart disease. Our diagnostic approach involves multiple testing, including blood and urine tests, used for the identification of biological markers associated with disease. Stool testing is also used to assess the health of a patient’s gut microbiota, as this is an important factor influencing heart disease.

Our proposed treatments depend on the type and severity of each patient’s condition and are based on the results obtained from our comprehensive testing. Typical treatments may involve a combination of standard medical approaches, with botanicals and probiotics, as well proposed changes in lifestyle factors such as diet and exercise levels. Ultimately, we seek to optimise the composition of your gut microbiota, in parallel with other factors affecting the health of your heart.

 

BECOME A PATIENT TODAY and reduce the risk of developing heart disease

 

 

 

References

 

  1. Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nature Reviews Immunology. 2013 Nov;13(11):790-801. Read it!
  2. Kamada N, Seo SU, Chen GY, Núñez G. Role of the gut microbiota in immunity and inflammatory disease. Nature Reviews Immunology. 2013 May;13(5):321-35. Read it!
  3. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007 Jul 1;56(7):1761-72. Read it!
  4. Taki K, Tsuruta Y, Niwa T. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. American journal of nephrology. 2007;27(1):30-5. Read it!
  5. Meijers BK, Verbeke K, Dehaen W, Vanrenterghem Y, Hoylaerts MF, Evenepoel P. The uremic retention solute p-cresyl sulfate and markers of endothelial damage. American journal of kidney diseases. 2009 Nov 1;54(5):891-901. Read it!
  6. Huttenhower C, Gevers D, Knight R, Abubucker S, Badger JH, Chinwalla AT, Creasy HH, Earl AM, FitzGerald MG, Fulton RS, Giglio MG. Structure, function and diversity of the healthy human microbiome. nature. 2012 Jun;486(7402):207. Read it!
  7. Hooper LV, Midtvedt T, Gordon JI. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annual review of nutrition. 2002 Jul;22(1):283-307. Read it!
  8. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, Pettersson S. Host-gut microbiota metabolic interactions. Science. 2012 Jun 8;336(6086):1262-7. Read it!
  9. Jia W, Li H, Zhao L, Nicholson JK. Gut microbiota: a potential new territory for drug targeting. Nature reviews Drug discovery. 2008 Feb;7(2):123-9. Read it!
  10. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. science. 2012 Jun 8;336(6086):1268-73. Read it!
  11. Quigley EM. Gut bacteria in health and disease. Gastroenterology & hepatology. 2013 Sep;9(9):560. Read it!
  12. Mahmoodpoor F, Saadat YR, Barzegari A, Ardalan M, Vahed SZ. The impact of gut microbiota on kidney function and pathogenesis. Biomedicine & Pharmacotherapy. 2017 Sep 1;93:412-9. Read it!
  13. Tang WW, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. The Journal of clinical investigation. 2014 Oct 1;124(10):4204-11. Read it!
  14. Allayee H, Hazen SL. Contribution of gut bacteria to lipid levels: another metabolic role for microbes? Read it!
  15. Nutting CW, Islam SA, Daugirdas JT. Vasorelaxant effects of short chain fatty acid salts in rat caudal artery. American Journal of Physiology-Heart and Circulatory Physiology. 1991 Aug 1;261(2):H561-7. Read it!
  16. Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J, von Haehling S, Schroedl W, Karhausen T, Doehner W, Rauchhaus M, Poole-Wilson P. Altered intestinal function in patients with chronic heart failure. Journal of the American College of Cardiology. 2007 Oct 16;50(16):1561-9. Read it!
  17. Sobko T, Huang L, Midtvedt T, Norin E, Gustafsson LE, Norman M, Jansson EÅ, Lundberg JO. Generation of NO by probiotic bacteria in the gastrointestinal tract. Free Radical Biology and Medicine. 2006 Sep 15;41(6):985-91. Read it!
  18. Hill MJ. Intestinal flora and endogenous vitamin synthesis. European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation (ECP). 1997 Mar 1;6:S43-5. Read it!
  19. Afsar B, Vaziri ND, Aslan G, Tarim K, Kanbay M. Gut hormones and gut microbiota: implications for kidney function and hypertension. Journal of the American Society of Hypertension. 2016 Dec 1;10(12):954-61. Read it!
  20. Lyte M. Probiotics function mechanistically as delivery vehicles for neuroactive compounds: microbial endocrinology in the design and use of probiotics. Bioessays. 2011 Aug;33(8):574-81. Read it!
  21. Matey-Hernandez ML, Williams FM, Potter T, Valdes AM, Spector TD, Menni C. Genetic and microbiome influence on lipid metabolism and dyslipidemia. Physiological genomics. 2018 Feb 1;50(2):117-26. Read it!
  22. Nakaya K, Ikewaki K. Microbiota and HDL metabolism. Current Opinion in Lipidology. 2018 Feb 1;29(1):18-23. Read it!
  23. Karlsson FH, Fåk F, Nookaew I, Tremaroli V, Fagerberg B, Petranovic D, Bäckhed F, Nielsen J. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nature communications. 2012 Dec 4;3(1):1-8. Read it!
  24. Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, Zadeh M, Gong M, Qi Y, Zubcevic J, Sahay B. Gut dysbiosis is linked to hypertension. Hypertension. 2015 Jun;65(6):1331-40. Read it!
  25. Kitai T, Tang WH. Gut microbiota in cardiovascular disease and heart failure. Clinical Science. 2018 Jan 16;132(1):85-91. Read it!
  26. Mitra S, Drautz-Moses DI, Alhede M, Maw MT, Liu Y, Purbojati RW, Yap ZH, Kushwaha KK, Gheorghe AG, Bjarnsholt T, Hansen GM. In silico analyses of metagenomes from human atherosclerotic plaque samples. Microbiome. 2015 Dec;3(1):1-4. Read it!
  27. Chistiakov DA, Bobryshev YV, Kozarov E, Sobenin IA, Orekhov AN. Role of gut microbiota in the modulation of atherosclerosis-associated immune response. Frontiers in microbiology. 2015 Jun 30;6:671. Read it!
  28. NCD Risk Factor Collaboration (NCD-RisC) (2017). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet (London, England), 389(10064), 37–55. Read it!
  29. Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, Zadeh M, Gong M, Qi Y, Zubcevic J, Sahay B. Gut dysbiosis is linked to hypertension. Hypertension. 2015 Jun;65(6):1331-40. Read it!
  30. Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, Wu S, Liu W, Cui Q, Geng B, Zhang W. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017 Dec;5(1):1-9. Read it!
  31. Pluznick JL. Renal and cardiovascular sensory receptors and blood pressure regulation. American Journal of Physiology-Renal Physiology. 2013 Aug 15;305(4):F439-44. Read it!
  32. Xu H, Wang X, Feng W, Liu Q, Zhou S, Liu Q, Cai L. The gut microbiota and its interactions with cardiovascular disease. Microbial Biotechnology. 2020 May;13(3):637-56. Read it!
  33. Lim GB. Gut flora—pathogenic role in chronic heart failure. Nature Reviews Cardiology. 2016 Feb;13(2):61-. Read it!
  34. Pasini E, Aquilani R, Testa C, Baiardi P, Angioletti S, Boschi F, Verri M, Dioguardi F. Pathogenic gut flora in patients with chronic heart failure. JACC: Heart Failure. 2016 Mar 1;4(3):220-7. Read it!
  35. Tang WW, Kitai T, Hazen SL. Gut microbiota in cardiovascular health and disease. Circulation research. 2017 Mar 31;120(7):1183-96. Read it!
  36. Koppel N, Bisanz JE, Pandelia ME, Turnbaugh PJ, Balskus EP. Discovery and characterization of a prevalent human gut bacterial enzyme sufficient for the inactivation of a family of plant toxins. Elife. 2018 May 15;7:e33953. Read it!
  37. Zhernakova A, Kurilshikov A, Bonder MJ, Tigchelaar EF, Schirmer M, Vatanen T, Mujagic Z, Vila AV, Falony G, Vieira-Silva S, Wang J. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science. 2016 Apr 29;352(6285):565-9. Read it!
  38. Fu J, Bonder MJ, Cenit MC, Tigchelaar EF, Maatman A, Dekens JA, Brandsma E, Marczynska J, Imhann F, Weersma RK, Franke L. The gut microbiome contributes to a substantial proportion of the variation in blood lipids. Circulation research. 2015 Oct 9;117(9):817-24. Read it!
  39. Taranto MP, Medici M, Perdigon G, Holgado AR, Valdez GF. Evidence for hypocholesterolemic effect of Lactobacillus reuteri in hypercholesterolemic mice. Journal of dairy science. 1998 Sep 1;81(9):2336-40. Read it!
  40. Kazemian N, Mahmoudi M, Halperin F, Wu JC, Pakpour S. Gut microbiota and cardiovascular disease: opportunities and challenges. Microbiome. 2020 Dec;8(1):1-7. Read it!